Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 3/2015

01.03.2015 | Review

Treatment cost evaluation of extrauterine gravidity: a literature review of medical and surgical treatment costs

verfasst von: Florian Ebner, Dominic Varga, Friederike Sorg, Elena Vorwerk, Fabienne Schochter, Wolfgang Janni, Achim Wöckel, Nikolaus DeGregorio

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The diagnosis of extrauterine pregnancy is possible very early giving the patient and doctors treatment options. As the risks and success rate of medical and surgical treatment are similar, the decision is increasingly influenced by cost-effectiveness.

Objective

The following article systematically reviews the known literature regarding cost, decision criteria and possible follow-up.

Methods

Literature review of extrauterine gravity in combination with cost in the online National Library of Medicine since 1.1.1997 following the PRISMA recommendations.

Results

Six articles were identified in which the cost of the laparoscopic versus medical treatment is reviewed. In five articles, the medical treatment was shown to be more cost effective and in the sixth article the costs were found to be equal. The cost saving varies between 18 and 88 % depending on the consideration of direct and indirect costs. If indirect expenses are considered, the total sum increases with treatment failures. Failure rates are given as up to 27 % depending on the type of failure (surgical or medical). These rates seem to be linked indirectly with the β-HCG levels. Predictive parameters for the successful medical treatment are missing.

Conclusions

The treatment of small extrauterine gravidities in haemodynamically stable patients (defined by HCG levels <1,500 IU/l) is medically successful and cost-effective. With HCG levels between 1,500 IU/l and 3,000 IU/l, the treatment costs are similar. HCG levels >5,000 IU/l favour the surgical treatment as being more cost-effective. A similar cut-off for the sonographic imaging is missing.
Literatur
1.
Zurück zum Zitat Agarwal N, Shahid A, Odejinmi F (2013) Caesarean scar pregnancy (CSP): a rare case of complete scar dehiscence due to scar ectopic pregnancy and its management-Springer. Arch Gynecol Obstet 288:231–232. doi:10.1007/s00404-012-2696-5 PubMedCrossRef Agarwal N, Shahid A, Odejinmi F (2013) Caesarean scar pregnancy (CSP): a rare case of complete scar dehiscence due to scar ectopic pregnancy and its management-Springer. Arch Gynecol Obstet 288:231–232. doi:10.​1007/​s00404-012-2696-5 PubMedCrossRef
2.
Zurück zum Zitat Deutsche Gesellschaft für Gynäkologie, und Geburtshilfe A für, Ultraschalldiagnostik (ARGUS) D et al. (2001) Leitlinie 015–032 Ultraschalluntersuchung in der Fruehschwangerschaft. Frauenarzt 327 ff Deutsche Gesellschaft für Gynäkologie, und Geburtshilfe A für, Ultraschalldiagnostik (ARGUS) D et al. (2001) Leitlinie 015–032 Ultraschalluntersuchung in der Fruehschwangerschaft. Frauenarzt 327 ff
4.
Zurück zum Zitat Lermann J, Segl P, Jud S et al (2014) Low-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008-Springer. Arch Gynecol Obstet 289:329–335. doi:10.1007/s00404-013-2982-x PubMedCrossRef Lermann J, Segl P, Jud S et al (2014) Low-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008-Springer. Arch Gynecol Obstet 289:329–335. doi:10.​1007/​s00404-013-2982-x PubMedCrossRef
6.
Zurück zum Zitat Mol F, Mol BW, Ankum WM et al (2008) Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 14:309–319. doi:10.1093/humupd/dmn012 PubMedCrossRef Mol F, Mol BW, Ankum WM et al (2008) Current evidence on surgery, systemic methotrexate and expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis. Hum Reprod Update 14:309–319. doi:10.​1093/​humupd/​dmn012 PubMedCrossRef
7.
Zurück zum Zitat Lécuru F, Robin F, Taurelle R (1997) Cost of the treatment of unruptured ectopic pregnancy: is there still a place for laparotomy? Am J Obstet Gynecol 177:1275–1276PubMedCrossRef Lécuru F, Robin F, Taurelle R (1997) Cost of the treatment of unruptured ectopic pregnancy: is there still a place for laparotomy? Am J Obstet Gynecol 177:1275–1276PubMedCrossRef
8.
Zurück zum Zitat Mol BW, Hajenius PJ, Ankum WM et al (1997) Comparative costs of methotrexate and laparoscopic surgery. Hum Reprod 12:1603–1604PubMedCrossRef Mol BW, Hajenius PJ, Ankum WM et al (1997) Comparative costs of methotrexate and laparoscopic surgery. Hum Reprod 12:1603–1604PubMedCrossRef
9.
Zurück zum Zitat Foulk RA, Steiger RM (1996) Operative management of ectopic pregnancy: a cost analysis. Am J Obstet Gynecol 175:90–96PubMedCrossRef Foulk RA, Steiger RM (1996) Operative management of ectopic pregnancy: a cost analysis. Am J Obstet Gynecol 175:90–96PubMedCrossRef
10.
Zurück zum Zitat Lowe PJ, Mamers PM, Sturrock TV, Healy D (1998) A casemix cost comparison of 2 treatments for ectopic pregnancy. Aust N Z J Obstet Gynaecol 38:333–335PubMedCrossRef Lowe PJ, Mamers PM, Sturrock TV, Healy D (1998) A casemix cost comparison of 2 treatments for ectopic pregnancy. Aust N Z J Obstet Gynaecol 38:333–335PubMedCrossRef
11.
Zurück zum Zitat Xiang XD, Tang YQ, Mao JF (1999) A comparison of laparoscopic surgery and laparotomy in the treatment of ectopic pregnancy. Singapore Med J 40:88–90PubMed Xiang XD, Tang YQ, Mao JF (1999) A comparison of laparoscopic surgery and laparotomy in the treatment of ectopic pregnancy. Singapore Med J 40:88–90PubMed
12.
Zurück zum Zitat Mol BW, Hajenius PJ, Engelsbel S et al (1997) An economic evaluation of laparoscopy and open surgery in the treatment of tubal pregnancy. Acta Obstet Gynecol Scand 76:596–600PubMedCrossRef Mol BW, Hajenius PJ, Engelsbel S et al (1997) An economic evaluation of laparoscopy and open surgery in the treatment of tubal pregnancy. Acta Obstet Gynecol Scand 76:596–600PubMedCrossRef
14.
Zurück zum Zitat Morlock RJ, Lafata JE, Eisenstein D (2000) Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstet Gynecol 95:407–412PubMedCrossRef Morlock RJ, Lafata JE, Eisenstein D (2000) Cost-effectiveness of single-dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstet Gynecol 95:407–412PubMedCrossRef
15.
Zurück zum Zitat Barnhart KT, Gosman G, Ashby R, Sammel M (2003) The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol 101:778–784PubMedCrossRef Barnhart KT, Gosman G, Ashby R, Sammel M (2003) The medical management of ectopic pregnancy: a meta-analysis comparing “single dose” and “multidose” regimens. Obstet Gynecol 101:778–784PubMedCrossRef
17.
Zurück zum Zitat Vaissade L, Gerbaud L, Pouly J-L et al (2003) Cost-effectiveness analysis of laparoscopic surgery versus methotrexate: comparison of data recorded in an ectopic pregnancy registry. J Gynecol Obstet Biol Reprod (Paris) 32:447–458 Vaissade L, Gerbaud L, Pouly J-L et al (2003) Cost-effectiveness analysis of laparoscopic surgery versus methotrexate: comparison of data recorded in an ectopic pregnancy registry. J Gynecol Obstet Biol Reprod (Paris) 32:447–458
18.
Zurück zum Zitat Sowter MC, Farquhar CM, Gudex G (2001) An economic evaluation of single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured ectopic pregnancy. BJOG 108:204–212PubMed Sowter MC, Farquhar CM, Gudex G (2001) An economic evaluation of single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured ectopic pregnancy. BJOG 108:204–212PubMed
19.
Zurück zum Zitat Lecuru F, Bernard JP, Mac-Cordick C et al (1998) Methotrexate provides significant cost savings for the treatment of unruptured ectopic pregnancy. Clin Drug Investig 15:405–411PubMedCrossRef Lecuru F, Bernard JP, Mac-Cordick C et al (1998) Methotrexate provides significant cost savings for the treatment of unruptured ectopic pregnancy. Clin Drug Investig 15:405–411PubMedCrossRef
20.
Zurück zum Zitat Mol BW, Hajenius PJ, Engelsbel S et al (1999) Treatment of tubal pregnancy in the netherlands: an economic comparison of systemic methotrexate administration and laparoscopic salpingostomy. Am J Obstet Gynecol 181:945–951PubMedCrossRef Mol BW, Hajenius PJ, Engelsbel S et al (1999) Treatment of tubal pregnancy in the netherlands: an economic comparison of systemic methotrexate administration and laparoscopic salpingostomy. Am J Obstet Gynecol 181:945–951PubMedCrossRef
22.
Zurück zum Zitat Hidlebaugh D, O’Mara P (1997) Clinical and financial analyses of ectopic pregnancy management at a large health plan. J Am Assoc Gynecol Laparosc 4:207–213PubMedCrossRef Hidlebaugh D, O’Mara P (1997) Clinical and financial analyses of ectopic pregnancy management at a large health plan. J Am Assoc Gynecol Laparosc 4:207–213PubMedCrossRef
23.
Zurück zum Zitat Lecuru F, Robin F, Chasset S et al (2000) Direct cost of single dose methotrexate for unruptured ectopic pregnancy. Prospective comparison with laparoscopy. Eur J Obstet Gynecol Reprod Biol 88:1–6PubMedCrossRef Lecuru F, Robin F, Chasset S et al (2000) Direct cost of single dose methotrexate for unruptured ectopic pregnancy. Prospective comparison with laparoscopy. Eur J Obstet Gynecol Reprod Biol 88:1–6PubMedCrossRef
Metadaten
Titel
Treatment cost evaluation of extrauterine gravidity: a literature review of medical and surgical treatment costs
verfasst von
Florian Ebner
Dominic Varga
Friederike Sorg
Elena Vorwerk
Fabienne Schochter
Wolfgang Janni
Achim Wöckel
Nikolaus DeGregorio
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 3/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3488-x

Weitere Artikel der Ausgabe 3/2015

Archives of Gynecology and Obstetrics 3/2015 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.